logo-loader
Synairgen PLC

Synairgen makes progress with lung drug

Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis

shutterstock_272949470.jpg
Syanairgen hopes to progress one of the Pharmaxis enzyme inhibitors to phase one trials next year

Respiratory drug group Synairgen plc (LON:SNG) has taken a step forward in developing a treatment for a fatal lung disease.

Synairgen announced positive results from its ongoing collaboration with Pharmaxis to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a novel treatment for idiopathic pulmonary fibrosis (IPF).

IPF results from the build-up of scar tissue, or fibrosis, in the lungs, which prevents normal uptake of oxygen. There are more than 100,000 IPF sufferers in the US alone.

The results of the experiments showed that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, could reduce cross-linking of collagen fibres - which results in fibrosis.

Synairgen will now focus on the pharmacology of the inhibitors and expects to progress one of them to phase one clinical trials in 2017.

Chief executive Richard Marsden said: "We are very pleased with the progress made with this collaboration and are excited by these results.

"We look forward to updating the markets with further progress over the coming months."

Meanwhile, Synairgen announced losses from operations for the year to December 31 of £2.61mln against profits of £1.09mln a year ago.

The profit a year ago was driven by a one-off upfront licensing payment from AstraZeneca PLC (LON:AZN) of £4.25mln.

The group said its current funds would support the ongoing search and identification of new potential molecule opportunities.

Chairman Simon Shaw said: "We are pleased with the progress made this year across our collaborations and in screening new opportunities.

"Our primary asset, AZD-9412, is being progressed through the clinic by AstraZeneca with results expected in 2017.

"Our strong balance sheet positions us well for progressing further collaborative programmes during the coming year."

Quick facts: Synairgen PLC

Price: £0.09

Market: AIM
Market Cap: £10.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read